Marvin L. White - 17 Jul 2025 Form 4 Insider Report for Aptevo Therapeutics Inc. (APVO)

Reporting relationship: President and CEO, Director
Issuer ticker: APVO
Reported as of: 17 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Jul 2025, 16:36:20 UTC
Prior SEC filing: 02 May 2025
Next SEC filing: 08 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ SoYoung Kwon, Attorney-In-Fact

Key filing fact

Marvin L. White filed Form 4 for Aptevo Therapeutics Inc. (APVO) on 21 Jul 2025.

Key facts

This page summarizes Marvin L. White's Form 4 filing for Aptevo Therapeutics Inc. (APVO).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 21 Jul 2025, 16:36.

Change

Previous filing in this sequence was filed on 02 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001493324 Primary reporting owner

White Marvin L

Relationship: President and CEO, Director
Address: 2401 4TH AVENUE, 1050, SEATTLE
Signature: /s/ SoYoung Kwon, Attorney-In-Fact
Signature date: 21 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

APVO transaction

Common Stock

Options Exercise

Transaction value
Shares: +10
Change %: +500%
Price
Shares after: 12
Date: 17 Jul 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APVO transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value: $0
Shares: -10
Change %: -33%
Price: $0.000000
Shares after: 20
Date: 17 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.

Footnote F2

On July 17, 2024, the reporting person was granted 22,325 (30 post-splits) RSUs, vesting in three approximately equal annual installments beginning on July 17, 2025.